Market Place
Sourcing Support
Ludwig Enterprises Begins PCR Validation Test Process
07 Nov 2024 //
ACCESSWIRE
Ludwig Enterprises Files Patent for Cancer Screening Algorithm
24 Oct 2024 //
ACCESSWIRE
Ludwig Announces Acquisition of Intellectual Property and Patent
17 Sep 2024 //
ACCESSWIRE
Ludwig Enterprises Files Patent On mRNA Screening For Cancer Detection
09 Jul 2024 //
ACCESSWIRE
Ludwig Enterprises Inc (OTC:LUDG) Funds Incurable Brain Cancer Study
27 Mar 2024 //
ACCESSWIRE
LudwigEnters Booming Artificial Intelligence Cancer Screening Market
19 Mar 2024 //
GLOBENEWSWIRE
Ludwig Announces Patent Filing for Breakthrough in Identifying mRNA Genes
06 Mar 2024 //
GLOBENEWSWIRE
Ludwig Enterprises mRNA Bladder Cancer Study to be Launched
31 Jan 2024 //
ACCESSWIRE
Ludwig Enterprises Appoints Scott Silverman as CFO
16 Nov 2023 //
ACCESSWIRE
Ludwig Enterprises Announces Effectiveness of Form S-1 Registration Application
14 Nov 2023 //
ACCESSWIRE
Ludwig Launches NuGenea, Groundbreaking Nutraceutical to Fight Inflammation
12 Apr 2023 //
ACCESSWIRE
Ludwig Enterprises Announces Agreement with Summit Bancorp
23 Mar 2023 //
ACCESSWIRE
Ludwig Enterprises Announces Intention to List on the Canadian Stock Exchange
21 Mar 2023 //
ACCESSWIRE
Ludwig Enterprises Developing New Partnerships to Fuel Growth
16 Mar 2023 //
ACCESSWIRE
Ludwig Enterprise mRNA Program Generating Broad Clinical Interest
14 Mar 2023 //
ACCESSWIRE
Ludwig Enterprises Announces Brand Name for Groundbreaking Nutraceutical
09 Mar 2023 //
ACCESSWIRE
Ludwig Enterprises Launches Growth Plan
14 Feb 2023 //
ACCESSWIRE
Ludwig Enterprises Receives IRB Approval on Bladder Cancer Study
03 Jan 2023 //
ACCESSWIRE
Ludwig Enterprises Acquires Cutting-Edge Dietary Supplement Formula
06 Dec 2022 //
ACCESSWIRE
Ludwig Cancer Research Study Finds Common, Targetable Mechanism Tumors
17 Nov 2022 //
SCIENCEDAILY
Ludwig Enterprises Announces Progress Towards Planned IPO (S1 Filing)
17 Nov 2022 //
ACCESSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.